CHRW acquires RXO for $30.25/share (29% premium). $300 mln synergies targeted. Leverage rises to 2.9x; buybacks paused until 2028. Shares down on premium, debt, dilution.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
